Conversion from mycophenolate mofetil to mizoribine for patients with positive polyomavirus type BK in urine
Conversion from mycophenolate mofetil to mizoribine for patients with positive polyomavirus type BK in urine
复制标题
DOI：
10.1016/j.transproceed.2008.07.069
复制
发表时间：
2008-09-01
影响因子：
0.9
通讯作者：
Gotoh, M.
中科院分区：
文献类型：
--
作者：
Funahashi, Y.;Hattori, R.;Gotoh, M.
已知给予吗替麦考酚酯（MMF）与肾移植受者的BK病毒（BKV）肾病相关。为了确定咪唑立宾对BKV的任何抑制作用，对7例尿中BKV阳性并服用MMF作为免疫抑制剂的患者在将MMF改为咪唑立宾后进行了评价。所有病例的基线尿液BKV DNA（范围为2.2 × 10（2）至5.5 × 10（6）拷贝/ml）均降低（平均值= 1.9 × 10（-1）倍;中位数2.8 × 10（-3）倍）。4例病例在6个月内转为阴性，1例在12个月内转为阴性。咪唑立宾给药期间未发生急性排斥反应或移植物功能恶化。咪唑立宾对BKV有抑制作用。
It is known that administration of mycophenolate mofetile (MMF) is associated with BK virus (BKV) nephropathy in renal transplant recipients. To determine any inhibitory effect of mizoribine for BKV, seven patients with positive BKV in their urine who took MMF as immunosuppressive therapy were evaluated after MMF was changed to mizoribine. Baseline BKV DNA in urine, which ranged from 2.2 x 10(2) to 5.5 X 10(6) copies per milliliter, decreased in all cases (mean = 1.9 x 10(-1) times; median 2.8 x 10(-3) times). Four cases turned negative within 6 months and one within 12 months. No acute rejection or deterioration of graft function occurred during the administration of mizoribine. An inhibitory effect of mizoribine on BKV was suggested.